Evaluation of the relationship between estrogen receptor immunohistochemical expression and Gleason score in prostate carcinoma

Document Type : Original Article


Department of Pathology, Faculty of Medicine, Jundishapur University of Medical Sciences, Ahvaz,, Iran


This study was aimed to evaluate the frequency of estrogen receptors in prostate carcinoma cells in order to better understand the relationship between estrogen receptors in malignant cells and pathology.
Materials and Methods
In this descriptive cross-sectional study, tissue paraffin blocks of patients referred to teaching hospitals of Ahvaz with pathologic diagnosis of prostate adenocarcinoma and benign prostatic hyperplasia were used. Clinical and demographic data of patients were extracted from hospital records. Immunohistochemical staining was performed using Anti ER monoclonal antibody.
In the present study, 30 prostate tissue specimens including 20 specimens with cancer and 10 specimens with benign hyperplasia were evaluated as control. The mean age of patients was 69.65 years. Estrogen receptor marker was expressed in only 25% of malignant samples. However, 100% of benign samples showed marker expression. ER marker expression was significantly correlated with Gleason score (p = 0.039).
Overall, the findings of this study indicate that the estrogen receptor is decreased in prostate malignancies and is more pronounced in higher grade tumors.


1-Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PloS one. 2011 Mar 4;6(3):e17449.
2-Kim SC, Jeong I, Song C, Hong JH, Kim CS, Ahn H. Biochemical recurrence-free and cancer-specific survival after radical prostatectomy at a single institution. Korean journal of urology. 2010 Dec 1;51(12):836-42.
3-Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. Journal of the National Cancer Institute. 2003 May 7;95(9):661-8.
4-Mandair D, Rossi RE, Pericleous M, Whyand T, Caplin ME. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab 2014; 11: 30.
5-Key TJ. Hormones and cancer in humans. Mutat Res 1995; 333: 59-67.
6-Balducci L, Khansur T, Smith T, Hardy C. Prostate cancer: a model of cancer in the elderly. Arch Gerontol Geriatr 1989; 8: 165-187.
7-Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostatic cancer: Ii. the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–23.
8-Koutsilieris M, Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. Prostate. 1985;7:31–9.
9-Klotz L, McNeill I, Fleshner N. A phase 1–2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol. 1999;161:169–72.
10-Gabal SM, Habib FM, Helmy DO, Ibrahim MF. Expression of estrogen receptor-B (ER-B ) in benign and malignant prostatic epithelial cells and its correlation with the clinico-pathological features. J. Egypt Natl. Canc. Inst. 2007;19:239–48.
11-Gallardo F, et al. Expression of androgen, oestrogen alpha and beta, and progesterone receptors in the canine prostate: differences between normal, inflamed, hyperplastic and neoplastic glands. J. Comp. Pathol. 2007;136:1–8.
12-Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer. 2004;11:537–51.
13-Konishi N, Nakaoka S, Hiasa Y, Kitahori Y, Ohshima M, Samma S, Okajima E. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. Oncology. 1993;50(4):259-63.
14-Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O’Neill G, Kooner R. Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer research. 2001 Jul 15;61(14):5331-5.
15-Gangkak G, Bhattar R, Mittal A, Yadav SS, Tomar V, Yadav A, Mehta J. Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia. Investigative and clinical urology. 2017 Mar 1;58(2):117-26.
16-Asgari M, Morakabati A. Estrogen receptor beta expression in prostate adenocarcinoma. Diagnostic pathology. 2011 Dec;6(1):61.